Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance

• Mirum Pharma: A Rare Disease Growth Story to Watch

Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the uncommon illness institution is entering a catalyst-heavy period, with caller affirmative objective updates, ongoing commercialized momentum for LIVMARLI and further concern improvement enactment expanding its portfolio.

Speaking astatine RBC Capital Markets’ 2026 Global Healthcare Conference, Peter Radovich, Mirum’s president and main operating officer, described the institution arsenic a planetary uncommon illness concern with astir 430 employees and 3 approved medicines. He said LIVMARLI remains the instauration of the company’s commercialized business, portion further assets acquired done concern improvement person broadened Mirum’s uncommon illness strategy.

→ Voya Financial Grows Earnings Across All 3 Business Segments

Radovich highlighted 2 caller objective readouts: affirmative pivotal information from the VISTAS survey of volixibat successful superior sclerosing cholangitis, oregon PSC, and Phase 2b interim results from the company’s hepatitis delta program, which came done Mirum’s acquisition of Bluejay Therapeutics. He said the institution is preparing for a pre-NDA gathering and an NDA submission for volixibat successful the 2nd fractional of the year, portion afloat Phase 3 readouts from the AZURE-1 and AZURE-4 hepatitis delta studies are expected aboriginal this year.

LIVMARLI Growth Driven by PFIC Demand

RBC biotech expert Lisa Walter noted that LIVMARLI generated $114 cardinal successful nett income successful the archetypal 4th of 2026, up 55% twelvemonth implicit year, and that Mirum raised full-year guidance to $660 cardinal to $680 million. Radovich said the cardinal operator was demand, peculiarly successful progressive familial intrahepatic cholestasis, oregon PFIC, wherever later-onset patients are progressively being identified among adolescents and adults.